Evaluating the Best Options for Successful Formulation Development.
Upperton’s talented R&D team have a breadth of experience and will confidently guide you on the best route forward for your pharmaceutical development program, by offering early stage proof of concept studies.
From sensitive Biologics to poorly soluble small molecule APIs, we have experience of developing successful spray dried formulations for a range of dosage forms.
Our skilled team are able to quickly evaluate the feasibility of spray drying to solve some of the pharmaceutical industries most pressing challenges. Upperton’s science led approach means we can do this with small amounts of material with a rapid turnaround of a couple of days.
Proof of concept studies at Upperton incorporate: solvent screening, spray drying SDDs (spray dried dispersions) and characterisation of both SDDs and API (active pharmaceutical ingredient).
Bioavailability Enhancement For Poorly Soluble Drugs
Stabilisation of Biologics
There is an ever increasing number of biotherapeutic entities currently entering the development pathway. Biologics are complex molecules ranging from small peptides to much larger proteins, monoclonal antibodies (mAbs) and vaccines. They all share the same properties in that they provide highly specific, targeted therapies for a range of clinical conditions.
Traditionally freeze drying (lyophilisation) is the method of choice for stabilising these sensitive molecules. Now more and more of our customers see spray drying as a more cost effective alternative with the added benefits of speed and scalability.
The Upperton team have worked on many proof of concept biologic projects and in doing so they have a deep understanding of the challenges associated with the handling, formulation and analysis of these highly complex molecules.